Boron-containing compounds on neurons: Actions and potential applications for treating neurodegenerative diseases

Boron-containing compounds (BCC) exert effects on neurons. After the expanding of both the identification and synthesis of new BCC, novel effects in living systems have been reported, many of these involving neuronal action. In this review, the actions of BCC on neurons are described; the effects have been inferred by boron deprivation or addition. Also, the effects can be related to those mediated by interaction on ionic channels, G-protein coupled receptors, or other receptors exerting modification on neuronal behavior. Additionally, BCC have exhibited effects by the modulation of inflammation or oxidative processes. BCC are expanding as drugs. Deprivation of boron sources from the diet shows the role of some natural BCC. However, the observations of several new synthesized compounds suggest their ability to act with attractive potency, efficacy, and long-term action on neuronal receptors or processes related with the origin and evolution of neurodegenerative processes. The details of BCC-target interactions are currently being elucidated in progress, as those observed from BCC-protein crystal complexes. Taking all of the above into account, the expansion is presumably near to having studies on the application of BCC as drugs on specific targets for treating neurodegenerative diseases.

Automated summary

Boron-containing compounds have effects on neurons, which have been inferred by boron deprivation or addition. These compounds can modify neuronal behavior by interacting with ionic channels, G-protein coupled receptors, or other receptors, and can also modulate inflammation or oxidative processes. Recent observations suggest that synthesized boron-containing compounds have attractive potency, efficacy, and long-term action on neuronal receptors or processes related to neurodegenerative diseases. Therefore, the application of these compounds as drugs for treating specific targets in neurodegenerative diseases is being expanded.